Novartis Ag (NVS) Other Accumulated Expenses (2009 - 2026)

Novartis Ag has reported Other Accumulated Expenses for 18 years, with the latest figure at -$100.0 million in Q1 2026.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to -$100.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$100.0 million (changed N/A YoY) and the FY2024 annual result came in at $14.1 billion, up 6.74% from the prior year.
• Other Accumulated Expenses fell to -$100.0 million in Q1 2026 per NVS's latest filing, from $15.8 billion in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $15.8 billion in Q2 2025 and troughed at -$100.0 million in Q1 2026.
• A 5-year average of $8.2 billion and a median of $13.2 billion in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses soared 1474.88% in 2023, then declined 10.14% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $836.0 million in 2022, then jumped by 1474.88% to $13.2 billion in 2023, then grew by 6.74% to $14.1 billion in 2024, then gained by 12.49% to $15.8 billion in 2025, then slumped by 100.63% to -$100.0 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered -$100.0 million, $15.8 billion, and $14.1 billion for Q1 2026, Q2 2025, and Q4 2024 respectively.